Yafei Biomedical Technology key facts
as of Oct 2026- Developer of a delivery system designed to cure tumours.
- Yafei Biomedical Technology is valued at approximately $843.9M as of Oct 2026 (last reported valuation).
- It has raised $106.3M; the latest was Later Stage VC ($41.8M) in Aug 2025.
- Notable investors include CMG SDIC Fund, China Growth Capital, Haiwang Capital, Chengdu Bio-Town Investment, Hongfu Investment — 19 tracked in total.
- Status: Privately Held (backing).
Yafei Biomedical Technology's last reported valuation, Nov 2024. Nothing priced has surfaced since.
- ·The complete investor list: 19 names
- ·Watch Yafei Biomedical Technology: the Monday email on marks, rounds and moves
Yafei Biomedical Technology funding rounds
No funding rounds for Yafei Biomedical Technology are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs Yafei Biomedical Technology
19+Yafei Biomedical Technology valuation
Yafei Biomedical Technology's last reported valuation was $844 million in Nov 2024. No priced round, secondary trade or fund mark has surfaced since.
Yafei Biomedical Technology investors
19 investors are on record for Yafei Biomedical Technology, including CMG SDIC Fund, China Growth Capital, Haiwang Capital and Chengdu Bio-Town Investment.
About Yafei Biomedical Technology
Developer of a delivery system designed to cure tumours. The company focuses on developing innovative anticancer drugs and chemical coupling technology, which upgrades traditional drug innovation to tumour microenvironment delivery, enabling improved drug efficacy and an expanded medication safety window.
- Sector
- Healthcare
- HQ
- Shanghai, China
- Founded
- 2012
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.